Unique ID issued by UMIN | UMIN000039947 |
---|---|
Receipt number | R000045550 |
Scientific Title | Follow-up of effectiveness in patients with inflammatory bowel diseases treated by ustekinumab and vedolizumab |
Date of disclosure of the study information | 2020/05/11 |
Last modified on | 2024/03/29 13:09:46 |
Follow-up of effectiveness in patients with inflammatory bowel diseases treated by ustekinumab and vedolizumab
UV follow-up study in IBD
Follow-up of effectiveness in patients with inflammatory bowel diseases treated by ustekinumab and vedolizumab
UV follow-up study in IBD
Japan |
ulcerative colitis and Crohn's disease
Medicine in general | Gastroenterology |
Others
NO
Evaluation of ustekinumab and vedolizumab-effects in prospective single-center observational study in IBD, such as ulcerative colitis and Crohn's disease patients
Efficacy
Persistence of ustekinumab and vedolizumab at week 56
Observational
18 | years-old | <= |
80 | years-old | >= |
Male and Female
Active IBD patients who will be treated with ustekinumab and vedolizumab
1. Patients with severe infection
2. Patients with active tuberculosis
3. Patients who has allergy against ustekinumab and vedolizumab
4. Maternal patients and patients with breastfeeding
5. Patients who has malignancy and who has past history of malignancy
6. Patients who has ostomy
7. Patients determined to be inappropriate for this study
80
1st name | Shingo |
Middle name | |
Last name | Kato |
Saitama Medical Center, Saitama Medical University
Department of Gastroenterology and Hepatology
350-8550
1981 Kamoda, Kawagoe City, Saitama 3508550, Japan
049-228-3564
skato@saitama-med.ac.jp
1st name | Shingo |
Middle name | kato |
Last name | Kato |
Saitama Medical Center, Saitama Medical University
Department of Gastroenterology and Hepatology
350-8550
1981 Kamoda, Kawagoe City, Saitama 3508550, Japan
049-228-3564
skato@saitama-med.ac.jp
Saitama Medical Center, Saitama Medical University
Saitama Medical Center, Saitama Medical University
Self funding
IRB of Saitama Medical Center
1981 Kamoda, Kawagoe City, Saitama 3508550, Japan
049-228-3902
smcrinri@saitama-med.ac.jp
NO
2020 | Year | 05 | Month | 11 | Day |
Unpublished
No longer recruiting
2020 | Year | 05 | Month | 07 | Day |
2020 | Year | 05 | Month | 14 | Day |
2020 | Year | 05 | Month | 18 | Day |
2025 | Year | 03 | Month | 31 | Day |
Decision of UST and VED is determined by doctor in clinical practice. All patients determined to be treated by VED were able to be enrolled in this study regardless of their clinical activities or history of treatment after the acquisition of informed consent. Shortening of vedolizumab treatment ever 4 weeks were not permitted in Japan.
2020 | Year | 03 | Month | 26 | Day |
2024 | Year | 03 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045550
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |